

*“Re: Explanation of Changes in Profit After  
Corporate Income Tax in the Reviewed Interim  
Financial Statements for the Six-Month Period Ended  
30 June 2025 compared to the same period last year”*

**To: - State Securities Commission of Vietnam;  
- Hanoi Stock Exchange.**

**1. Company name: Danang Pharmaceutical – Medical Equipment Joint Stock  
Company**

2. Stock code: DDN (Upcom)

3. Head office: 02 Phan Dinh Phung, Hai Chau Ward, Danang City

4. Telephone: 0236.3822247 Fax: 0236.3891752

**Published information content:**

Pursuant to Circular No. 96/2020/TT-BTC dated November 16, 2020, Danang Pharmaceutical – Medical Equipment Joint Stock Company hereby provides the following explanation:

The profit after corporate income tax in the reviewed interim financial statements for the six-month period ended 30 June 2025 has increased/decreased by 10% or more compared with that of the same period in the previous year.:

<b>Indicator</b>	<b>Interim Financial Statements for the Six-Month Period Ended 30 June 2025</b>	<b>Interim Financial Statements for the Six-Month Period Ended 30 June 2024</b>	<b>Difference (%)</b>
Cumulative profit after corporate income tax for the six-month period ended 30 June 2025	1,266,434,672 VND	4,503,624,347 VND	-71.9%

**Details:**

The cumulative profit after corporate income tax for the six-month period ended 30 June 2025 decreased by 71.9% compared to the same period in 2024 due to the Company's investment in expanding the NeoVita vaccination center and healthcare service network in Ho Chi Minh City.

**Recipients:**

- As above;
- Company website;
- Filed at Office.

**GENERAL DIRECTOR**



**NGUYEN LUONG TAM**